About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of AZD9829 in CD123+ Hematological Malignancies

NCT06179511·22 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

≥18 years of age;
CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;
* R/R AML (except APL);
* R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;
Had at least 1 prior line of therapy at currents histology, and have no available treatment options;
ECOG performance status of ≤ 2.

You may not be if

Active CNS leukemia;
Previous treatment with any CD123 targeting therapy;
Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;
Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;
History of other malignancy(with certain exceptions);
Active and uncontrolled infections;
Unresolved AEs ≥2 Grade, from prior therapies.

The record

StatusCompleted

PhasePhase 1–2

Taking part56

StartedJan 2024

UpdatedJul 1, 2026

Conditions

Hematological Malignancies

Where22

Research Site
Duarte, California, United States
Research Site
St Louis, Missouri, United States
Research Site
New York, New York, United States

Clareo Health | Study of AZD9829 in CD123+ Hematological Malignancies